ASCO 2025

May 30 - June 03, 2025
Chicago, IL

American Society of Clinical Oncology 2025
Explore more Oncology congress materials
Material Type

Results(7)

Oncology
Hematology
Concordance Analysis Between Tumor Tissue Human Epidermal Growth Factor Receptor 2 Status by Immunohistochemistry and In Situ Hybridization and a Translational Analysis of Plasma Circulating Tumor DNA in Patients With Biliary Tract Cancer: An Exploratory
Author(s): James J. Harding, Jin Won Kim, Do-Youn Oh et al.
Safety and efficacy of lurbinectedin plus atezolizumab as second-line treatment for advanced small-cell lung cancer: Results of the 2SMALL phase 1/2 study
Author(s): Santiago Ponce Aix, Alejandro Navarro, Maria Eugenia Olmedo García et al.
Safety and efficacy of lurbinectedin plus atezolizumab as second-line treatment for advanced small-cell lung cancer: Results of the 2SMALL phase 1/2 study
Author(s): Santiago Ponce Aix, Alejandro Navarro, Maria Eugenia Olmedo García et al.
Lurbinectedin + atezolizumab as first-line maintenance treatment in patients with extensive-stage small cell lung cancer: Primary results of the Phase 3 IMforte trial
Author(s): Luis Paz-Ares, Hossein Borghaei, Stephen V. Liu et al.
Long-term outcomes and overall survival for zanidatamab + chemotherapy in HER2-positive advanced or metastatic gastroesophageal adenocarcinoma: 4-year follow-up of a phase 2 trial
Author(s): Elena Elimova, Jaffer Ajani, Howard Burris et al.
V-RULES: Real-World Effectiveness and Safety of CPX-351 in Patients With Secondary Acute Myeloid Leukemia (AML)
Author(s): Thomas W. LeBlanc, Catherine Lai, Amir Ali et al.
Survival Outcomes for Zanidatamab Compared to Chemotherapy in Previously Treated HER2-Positive (IHC 3+) Biliary Tract Cancer: HERIZON‑BTC-01 vs a Real-World External Control Arm
Author(s): Richard Kim, Xiaozhou Fan, Javier Sabater et al.